Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30179366 | 0.92 | MDM4 (0.46) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL30040454 | 0.90 | MDM4 (0.45) | MDM4TP53KMT2AMDM2TLR2 | |
| SCHEMBL30179717 | 0.84 | PTPN1 (0.44) | MDM4TP53MDM2PTPN1 | |
| SCHEMBL23073318 | 0.84 | PTPN1 (0.42) | PTPN1 | |
| SCHEMBL29622972 | 0.83 | TLR2 (0.43) | KMT2AMDM2TLR2PTPN1 | |
| SCHEMBL29793310 | 0.81 | KMT2A (0.49) | MDM4TP53KMT2AMDM2TLR2 | |
| SCHEMBL9596624 | 0.81 | CASP3 (0.49) | MDM4TP53KMT2AMDM2PTPN1 | |
| SCHEMBL1405816 | 0.81 | MDM4 (0.54) | MDM4TP53KMT2AMDM2CASP3 | |
| SCHEMBL1486208 | 0.81 | MDM4 (0.54) | MDM4TP53KMT2AMDM2CASP3 | |
| SCHEMBL29353891 | 0.81 | MDM4 (0.54) | MDM4TP53KMT2AMDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4317171-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2024-02-07 | — | — | EP | disclosed |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | ANYGEN CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| WO-2023038464-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | 애니젠 주식회사 | 2023-03-16 | — | — | WO | disclosed |
| EP-4119570-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2023-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | GPR119, GPR39, FABP4 | MDM4 4687/4885TP53 4423/4885KMT2A 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.